2021 Year in Review: Top News and Insights in Cell Therapy

2021 has been a monumental year for cell therapies, with 3 new CAR T-cell therapy approvals by the FDA indicated for hematologic malignancies. With several more clinical trials still underway, 2022 is shaping up to offer even more advances in this exciting therapeutic category.

GeneTherapyLive has brought you coverage of these key advancements throughout the year, including the latest study data and clinical insights from experts in the field. Let's review some of our most-viewed coverage of cell therapies from 2021 below:

1. CAR T-Cell Therapy Plus Amplifying Vaccine Shows Initial Safety, Efficacy in Solid Tumors

BNT211, a CLDN6 chimeric antigen receptor (CAR) T-cell candidate, has shown signs of efficacy in solid tumors with a favorable safety profile, both alone and in combination with a CAR-T cell amplifying RNA vaccine (CARVac). READ MORE

2. Natural Killer Cell Therapy Well Tolerated in Solid Tumors

Acepodia presented positive data on their lead program, ACE1702, an allogeneic, amplified natural killer (NK) cell therapy for HER2-positive solid tumors. READ MORE

3. Targeting Relapsing/Refractory Multiple Myeloma With Cell Therapy

The president and chief operating officer of Agenus discussed the cell therapies the company is developing for the treatment of multiple myeloma. WATCH NOW

4. TCR-T Cell Therapy Cleared for Phase 1/2 Study in Acute Myeloid Leukemia

The FDA has accepted Intellia Therapeutics’ investigational new drug application for NTLA-5001, an investigational CRISPR/Cas9 T cell receptor (TCR)-T cell therapy for the potential treatment of acute myeloid leukemia. READ MORE

5. Utility of CAR T-Cell Therapy in Relapsed Multiple Myeloma: Thomas G. Martin, MD

The co-leader of Cancer Immunology & Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center discussed the utility of CAR T-cell therapy in late relapsed multiple myeloma. WATCH NOW